Skip to main content

Research Repository

Advanced Search

All Outputs (19)

681 USING NANOPORE SEQUENCING TO DIAGNOSE PROSTHETIC JOINT INFECTIONS (2024)
Presentation / Conference
Wilkinson, H., Cool, P., Perry, J., Wright, K. T., McCarthy, H. S., & Hulme, C. H. (2024, April). 681 USING NANOPORE SEQUENCING TO DIAGNOSE PROSTHETIC JOINT INFECTIONS. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

275 PATIENTS LIVING IN AREAS OF HIGHER SOCIOECONOMIC AREA DEPRIVATION HAVE SIGNIFICANTLY POORER PATIENT-REPORTED OUTCOMES FOLLOWING AUTOLOGOUS CHONDROCYTE IMPLANTATION IN THE UNITED KINGDOM (2024)
Presentation / Conference
Ismael, S., McCarthy, H. S., Williams, M., Barnett, A., Gallacher, P., Jermin, P., …Kuiper, J. H. (2024, April). 275 PATIENTS LIVING IN AREAS OF HIGHER SOCIOECONOMIC AREA DEPRIVATION HAVE SIGNIFICANTLY POORER PATIENT-REPORTED OUTCOMES FOLLOWING AUTOLOGOUS CHONDROCYTE IMPLANTATION IN THE UNITED KINGDOM. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

284 Lower Cell Number Implanted is Consistently Associated with Improved Functional Outcome Post-Autologous Chondrocyte Implantation in Longitudinal Multilevel Modelling Analyses. (2024)
Presentation / Conference
Kuiper, J. H., Dewan, V., Tierney, L., Roberts, S., Harrison, P., Gallacher, P., …Wright, K. T. (2024, April). 284 Lower Cell Number Implanted is Consistently Associated with Improved Functional Outcome Post-Autologous Chondrocyte Implantation in Longitudinal Multilevel Modelling Analyses. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

344 CO-DESIGNING ACCEPTABLE, FEASIBLE TRIALS TO TEST DRUGS TARGETING PREVENTION OF POST-TRAUMATIC OSTEOARTHRITIS AFTER KNEE INJURY: PIPEDREAM OR REALITY? (2024)
Presentation / Conference
Kalsoum, R., Brewer, G., Lowe, C. M., Papadaki, A., Nigrelli, L., Gilbert, S., …Watt, F. E. (2024, April). 344 CO-DESIGNING ACCEPTABLE, FEASIBLE TRIALS TO TEST DRUGS TARGETING PREVENTION OF POST-TRAUMATIC OSTEOARTHRITIS AFTER KNEE INJURY: PIPEDREAM OR REALITY?. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

361 ADDITION OF THROMBIN TO BONE MARROW CONCENTRATE DURING THE TREATMENT OF ANKLE CARTILAGE DEFECTS SIGNIFICANTLY INCREASES THE CONCENTRATION OF INTERLEUKIN-1 RECEPTOR ALPHA AND PLATELET-DERIVED GROWTH FACTOR BB (2024)
Presentation / Conference
Lan, T., Wright, K. T., Makwana, N., Bing, A., McCarthy, H. S., & Hulme, C. H. (2024, April). 361 ADDITION OF THROMBIN TO BONE MARROW CONCENTRATE DURING THE TREATMENT OF ANKLE CARTILAGE DEFECTS SIGNIFICANTLY INCREASES THE CONCENTRATION OF INTERLEUKIN-1 RECEPTOR ALPHA AND PLATELET-DERIVED GROWTH FACTOR BB. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

444 Differential Transcriptome Signatures of Success are Identified within Different Cell Populations used for Treating Cartilage Defects in the Knee (2024)
Presentation / Conference
Tierney, L., Jones, A., McCarthy, H. S., Roberts, S., Tonge, D., & Wright, K. T. (2024, April). 444 Differential Transcriptome Signatures of Success are Identified within Different Cell Populations used for Treating Cartilage Defects in the Knee. Poster presented at 2024 OARSI World Congress on Osteoarthritis, Vienna, Austria

Analysis of Synovial Fluid Proteomes After Treating an Ovine Osteoarthritic Model with Human Umbilical Cord Mesenchymal Stem Cells (2023)
Presentation / Conference
McDonald, J., Wright, K., Mennan, C., Peffers, M., Perry, J., Roberts, S., …Hulme, C. (2023, September). Analysis of Synovial Fluid Proteomes After Treating an Ovine Osteoarthritic Model with Human Umbilical Cord Mesenchymal Stem Cells. Presented at International Cartilage and Joint Preservation Society World Congress 2023, Melia Hotel Sitges, Sitges/ Barcelona

Umbilical Cord MSC Treated Osteoarthritic Sheep Display Reduced Radiographic Changes: Proteomic Biomarker Profiling of Synovial Fluids Implicate an Immunomodulatory Mechanism (2023)
Presentation / Conference
Perry, J., Mennan, C., Cool, P., Mccarthy, H., Newell, K., Hulme, C., …Roberts, S. (2023, March). Umbilical Cord MSC Treated Osteoarthritic Sheep Display Reduced Radiographic Changes: Proteomic Biomarker Profiling of Synovial Fluids Implicate an Immunomodulatory Mechanism. Presented at TERMIS 2023 – European Chapter, Manchester Central Conference Centre Manchester, UK

Matrix mettaloproteinase-3 (MMP-3) and tissue inhibitors of metalloproteinases-1 (TIMP-1): potential biomarkers to predict the outcome of Autologous Chondrocyte Implantation (2019)
Presentation / Conference
Hulme, C., Roberts, S., Gallacher, P., Jermin, P., Richardson, J., & Wright, K. (2019, October). Matrix mettaloproteinase-3 (MMP-3) and tissue inhibitors of metalloproteinases-1 (TIMP-1): potential biomarkers to predict the outcome of Autologous Chondrocyte Implantation. Paper presented at International Joint and Cartilage Preservation Society (ICRS) 2019, Vancouver, Canada

Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs) (2018)
Presentation / Conference
Hulme, C., Wilson, E., Fuller, H., Roberts, S., Richardson, J., Gallacher, P., …Wright, K. (2018, July). Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs). Poster presented at Matrix Biology Europe – July 2018 Meeting Celebrating 50 years of Federation of European Connective Tissue Societies Meetings, Manchester, United Kingdom

Introduction: Autologous chondrocyte implantation (ACI) is a cell therapy used to treat cartilage defects and early osteoarthritis. During initial surgery (Stage I), healthy cartilage is harvested from the joint. Chondrocytes are isolated and culture... Read More about Identification of synovial fluid proteins that are associated with early osteoarthritis treatment failure: the search for novel markers leads us back to matrix metalloproteinases (MMPs).

Facilitating the operational readiness of the NHS for the in-house manufacture and delivery of autologous cell therapy (2017)
Presentation / Conference
Ziya, S., Medcalf, N., El, A., & Wright, K. (2017, June). Facilitating the operational readiness of the NHS for the in-house manufacture and delivery of autologous cell therapy. Poster presented at ISCT 2017 Annual Meeting, London, UK

Introduction: Cell-based therapies (CBTs) have been shown to confer regenerative capacity in various pathologies. The production of such treatments require a range of business models. These business models either align with or disrupt the current c... Read More about Facilitating the operational readiness of the NHS for the in-house manufacture and delivery of autologous cell therapy.

The Up-Scale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies
Presentation / Conference
Mennan, C., Hulme, C., Garcia, J., Perry, J., Roberts, S., Norris, K., …Wright, K. T. The Up-Scale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies. Poster presented at TERMIS-EU 2020 Chapter Meeting

INTRODUCTION: Up-scaled allogeneic cellular products for cartilage therapies, along with identification of novel young donors of healthy chondrocytes, are needed to improve the cost effectiveness and wide-spread use of chondrocyte therapy. METHODS... Read More about The Up-Scale Manufacture of Chondrocytes for Allogeneic Cartilage Therapies.

Juvenile Chondrocytes: Novel Alternatives for Allogeneic Cell Therapy?
Presentation / Conference
Hulme, C., & Wright, K. Juvenile Chondrocytes: Novel Alternatives for Allogeneic Cell Therapy?. Presented at International Cartilage Regeneration and Joint Preservation Society (ICRS) World Congress 2022

Purpose Development of novel allogeneic chondrocyte therapies are needed to provide a more widespread, cost-effective cartilage treatment option. Here we investigate the potential of juvenile cartilage sources for allogeneic chondrocyte manufactur... Read More about Juvenile Chondrocytes: Novel Alternatives for Allogeneic Cell Therapy?.